
A new study suggests that targeting the enzyme transglutaminase 2 (TG2) could be a potential treatment for systemic sclerosis (SSc), a condition characterized by excessive crosslinking of proteins in fibrotic tissues. Researchers found that TG2 expression and activity were elevated in SSc patients, particularly those with interstitial lung disease. Inhibitory anti-TG2 antibodies effectively reduced dermal thickening, myofibroblast differentiation, and collagen accumulation in a 3D model of human skin. These findings indicate that TG2 inhibition could be an antifibrotic strategy for SSc. Clinical trials evaluating anti-TG2 antibodies for other conditions may pave the way for future studies in SSc.
Like
Save
Share